# Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage

> **NCT07662174** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Post-hemorrhagic Hydrocephalus (PHH)

## Interventions

- **DRUG:** Sirolimus (Rapamune®)

## Key facts

- **NCT ID:** NCT07662174
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662174, "Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*